AMG 176 + Azacitidine
Phase 1Terminated 0 views this week 0 watching💤 Quiet
Interest: 21/100
21
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Higher Risk Myelodysplastic Syndrome
Conditions
Higher Risk Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia
Trial Timeline
Nov 14, 2022 → Dec 19, 2023
NCT ID
NCT05209152About AMG 176 + Azacitidine
AMG 176 + Azacitidine is a phase 1 stage product being developed by Amgen for Higher Risk Myelodysplastic Syndrome. The current trial status is terminated. This product is registered under clinical trial identifier NCT05209152. Target conditions include Higher Risk Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia.
Hype Score Breakdown
Clinical
6
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05209152 | Phase 1 | Terminated |
Competing Products
2 competing products in Higher Risk Myelodysplastic Syndrome
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| AK117 + Placebo + Azacitidine | Akeso | Phase 2 | 42 |
| evorpacept + azacitidine | ALX Oncology | Phase 1 | 11 |